Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab extension study in SLE
NCT01408576Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2011
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of epratuzumab in systemic lupus erythematosus (SLE), sponsored by UCB. Started Jul 2011; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01408576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01408576.